Retatrutide
🔬 Overview
Retatrutide is an investigational triple receptor agonist that acts on the GIP, GLP-1, and glucagon receptors at once. It is the newest of the incretin-based compounds and remains in clinical trials, meaning it is not an approved medicine anywhere.
Research interest centres on metabolic effects and body weight in trial settings. Because it hits three pathways, it is studied separately from single or dual agonists such as semaglutide and tirzepatide.
💉 Research-Reported Dosing
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Research start | 1 mg | Once weekly | Low starting point, slow titration |
| Titration | 2 mg | Once weekly | Step up after several weeks |
| Higher range | 3-4 mg | Once weekly | Upper research range |
Figures are drawn from research literature and community protocols. They are not dosing recommendations. Use the dosage calculator to convert any amount into a syringe volume.
⚗️ Reconstitution & Solubility
- Bring the lyophilised vial and bacteriostatic water to room temperature
- Swab both stoppers with alcohol and let dry
- Add your chosen volume of bacteriostatic water down the vial wall
- Swirl gently until clear, do not shake
- Store refrigerated at 2 to 8 C once reconstituted
📍 Administration
Administered by subcutaneous injection in research settings, typically once weekly given the long half-life. Rotate injection sites. Convert your weekly milligram amount into a syringe volume with the calculator.
📚 Research Notes
Trial data has focused on metabolic and weight endpoints. Reported effects mirror the incretin class: gastrointestinal effects such as nausea are the most common, usually dose related and reduced by slow titration.
⚠️ Safety & Disclaimer
Retatrutide is an investigational drug still in clinical trials, not an approved medicine. It is sold only as a research chemical. Incretin agonists carry known risks including gastrointestinal effects, gallbladder issues, pancreatitis signals, and a class warning regarding thyroid C-cell tumours in rodents. This is not medical advice and it is not for human use. Any human use should only ever occur under qualified medical supervision.